Medline Inc. (MDLN) stock forecast and price target
Price $39.47 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($39.47)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $1.57 | +19.0% | $31.4B |
| Next fiscal year ends December 31, 2027 | $1.54 | −1.8% | $33.9B |
| Next quarter ends December 31, 2026 | $0.40 | +28.0% | $8.5B |
| Quarter after ends March 31, 2027 | $0.34 | +2.7% | $7.9B |
Consensus of the analysts covering Medline, updated daily. In the last 30 days 12 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 14.9% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Medline’s intrinsic value about 48% below today’s market value, and it scores 1.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Medline stock price target?
The average 12-month target from 26 analysts is $45.35, 14.9% above the current price of $39.47 Targets range from $34.00 to $55.00.
Is Medline a buy according to analysts?
The consensus rating is “Buy” (6 strong buy, 16 buy, 5 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Medline expected to earn?
Analysts expect EPS of $1.57 for the fiscal year ending December 31, 2026 and $1.54 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.